Abstract
The last few years have seen a resurgence of activity in the hepatitis B drug pipeline, with many compounds in various stages of development. This review aims to provide a comprehensive overview of the latest advances in therapeutics for chronic hepatitis B (CHB). We will discuss the broad spectrum of direct-acting antivirals in clinical development, including capsids inhibitors, siRNA, HBsAg and polymerase inhibitors. In addition, host-targeted therapies (HTT) will be extensively reviewed, focusing on the latest progress in immunotherapeutics such as toll-like receptors and RIG-1 agonists, therapeutic vaccines and immune checkpoints modulators. A growing number of HTT in pre-clinical development directly target the key to HBV persistence, namely the covalently closed circular DNA (cccDNA) and hold great promise for HBV cure. This exciting area of HBV research will be highlighted, and molecules such as cyclophilins inhibitors, APOBEC3 deaminases and epigenetic modifiers will be discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 1111-1132 |
| Number of pages | 22 |
| Journal | Virulence |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2022 |
| Externally published | Yes |
ASJC Scopus subject areas
- Parasitology
- Microbiology
- Immunology
- Microbiology (medical)
- Infectious Diseases
Keywords
- cccDNA
- Chronic hepatitis B
- direct-acting antivirals
- host-targeted therapies
- therapeutic targets
